Aimee L Mcrae-Clark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7072942/publications.pdf

Version: 2024-02-01

88 papers

3,857 citations

35 h-index 59 g-index

89 all docs 89 docs citations

89 times ranked 4002 citing authors

#	Article	IF	CITATIONS
1	Review of sertraline and its clinical applications in psychiatric disorders. Expert Opinion on Pharmacotherapy, 2001, 2, 883-892.	1.8	267
2	A Double-Blind Randomized Controlled Trial of $\langle i \rangle N \langle i \rangle$ -Acetylcysteine in Cannabis-Dependent Adolescents. American Journal of Psychiatry, 2012, 169, 805-812.	7.2	245
3	Stress reactivity: biological and subjective responses to the cold pressor and Trier Social stressors. Human Psychopharmacology, 2006, 21, 377-385.	1.5	170
4	Safety and Tolerability of Nâ€Acetylcysteine in Cocaineâ€Dependent Individuals. American Journal on Addictions, 2006, 15, 105-110.	1.4	149
5	Treatment of Cannabis Use Disorder: Current Science and Future Outlook. Pharmacotherapy, 2016, 36, 511-535.	2.6	136
6	Reactivity to laboratory stress provocation predicts relapse to cocaine. Drug and Alcohol Dependence, 2010, 106, 21-27.	3.2	129
7	Treatment of marijuana dependence: a review of the literature. Journal of Substance Abuse Treatment, 2003, 24, 369-376.	2.8	115
8	Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology, 2013, 228, 623-631.	3.1	114
9	Determining menstrual phase in human biobehavioral research: A review with recommendations Experimental and Clinical Psychopharmacology, 2016, 24, 1-11.	1.8	111
10	A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence, 2017, 177, 249-257.	3.2	109
11	A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology, 2013, 226, 721-737.	3.1	85
12	Cold Pressor Task Reactivity: Predictors of Alcohol Use Among Alcohol-Dependent Individuals With and Without Comorbid Posttraumatic Stress Disorder. Alcoholism: Clinical and Experimental Research, 2006, 30, 938-946.	2.4	84
13	The relationship between years of cocaine use and brain activation to cocaine and response inhibition cues. Addiction, 2014, 109, 2062-2070.	3.3	76
14	A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug and Alcohol Dependence, 2009, 105, 132-138.	3.2	73
15	PTSD and the HPA axis: Differences in response to the cold pressor task among individuals with child vs. adult trauma. Psychoneuroendocrinology, 2006, 31, 501-509.	2.7	71
16	A Placeboâ€Controlled Trial of Atomoxetine in Marijuanaâ€Dependent Individuals with Attention Deficit Hyperactivity Disorder. American Journal on Addictions, 2010, 19, 481-489.	1.4	70
17	Association of elevated cytokines with childhood adversity in a sample of healthy adults. Journal of Psychiatric Research, 2013, 47, 604-610.	3.1	70
18	Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. Psychopharmacology, 2011, 218, 49-58.	3.1	67

#	Article	IF	CITATIONS
19	Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. American Journal on Addictions, 2017, 26, 136-144.	1.4	64
20	Effects of gender and cigarette smoking on reactivity to psychological and pharmacological stress provocation. Psychoneuroendocrinology, 2008, 33, 560-568.	2.7	62
21	Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety, 2004, 19, 190-196.	4.1	56
22	Brain activation to cocaine cues and motivation/treatment status. Addiction Biology, 2014, 19, 240-249.	2.6	54
23	Is Cocaine Desire Reduced by <char aid="99897189" id="ital">N</char> -Acetylcysteine?. American Journal of Psychiatry, 2007, 164, 1115.	7.2	53
24	D-Cycloserine and Cocaine Cue Reactivity: Preliminary Findings. American Journal of Drug and Alcohol Abuse, 2009, 35, 434-438.	2.1	52
25	Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence. Psychiatry Research, 2015, 229, 94-100.	3.3	52
26	Community-dwelling cocaine-dependent men and women respond differently to social stressors versus cocaine cues. Psychoneuroendocrinology, 2010, 35, 798-806.	2.7	49
27	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug and Alcohol Dependence, 2020, 212, 107993.	3.2	49
28	Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug and Alcohol Dependence, 2015, 156, 29-37.	3.2	48
29	A randomized, placebo-controlled laboratory study of the effects of d-cycloserine on craving in cocaine-dependent individuals. Psychopharmacology, 2013, 226, 739-746.	3.1	47
30	Differences in Early Onset Alcohol Use and Heavy Drinking among Persons with Childhood and Adulthood Trauma. American Journal on Addictions, 2007, 16, 439-442.	1.4	46
31	Determinants of Cue-Elicited Craving and Physiologic Reactivity in Methamphetamine-Dependent Subjects in the Laboratory. American Journal of Drug and Alcohol Abuse, 2010, 36, 106-113.	2.1	46
32	Prospective associations between brain activation to cocaine and no-go cues and cocaine relapse. Drug and Alcohol Dependence, 2013, 131, 44-49.	3.2	46
33	Response to Corticotropin-Releasing Hormone Infusion in Cocaine-Dependent Individuals. Archives of General Psychiatry, 2009, 66, 422.	12.3	43
34	Achieving Cannabis Cessation â€" Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemporary Clinical Trials, 2014, 39, 211-223.	1.8	42
35	Buspirone for Treatment of Marijuana Dependence: A Pilot Study. American Journal on Addictions, 2006, 15, 404-404.	1.4	37
36	Motives for using: A comparison of prescription opioid, marijuana and cocaine dependent individuals. Addictive Behaviors, 2012, 37, 373-378.	3.0	35

#	Article	IF	CITATIONS
37	Relationship between Child Abuse and Adult Smoking. International Journal of Psychiatry in Medicine, 2009, 39, 417-426.	1.8	34
38	Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women. Addictive Behaviors, 2016, 60, 197-202.	3.0	33
39	Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug and Alcohol Dependence, 2018, 182, 1-7.	3.2	30
40	Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Research, 2017, 249, 318-320.	3.3	29
41	Impact of DCS-facilitated cue exposure therapy on brain activation to cocaine cues in cocaine dependence. Drug and Alcohol Dependence, 2013, 132, 195-201.	3.2	27
42	A Randomized, Placebo- controlled trial of Buspirone for the Treatment of Anxiety in Opioid-dependent Individuals. American Journal on Addictions, 2004, 13, 53-63.	1.4	26
43	Does Alexithymia Explain Variation in Cueâ€Elicited Craving Reported by Methamphetamineâ€Dependent Individuals?. American Journal on Addictions, 2012, 21, 130-135.	1.4	26
44	Contingency Management in Community Programs Treating Adolescent Substance Abuse: A Feasibility Study. Journal of Child and Adolescent Psychiatric Nursing, 2012, 25, 33-41.	1.4	26
45	Vilazodone for cannabis dependence: A randomized, controlled pilot trial. American Journal on Addictions, 2016, 25, 69-75.	1.4	26
46	Daily stressor sensitivity, abuse effects, and cocaine use in cocaine dependence. Addictive Behaviors, 2007, 32, 3015-3025.	3.0	25
47	Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. American Journal of Drug and Alcohol Abuse, 2018, 44, 47-55.	2.1	25
48	Extinction of drug cue reactivity in methamphetamine-dependent individuals. Behaviour Research and Therapy, 2010, 48, 860-865.	3.1	23
49	Resisting the Urge to Smoke and Craving during a Smoking Quit Attempt on Varenicline: Results from a Pilot FMRI Study. American Journal of Drug and Alcohol Abuse, 2013, 39, 92-98.	2.1	23
50	Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence. Journal of Substance Abuse Treatment, 2015, 57, 70-74.	2.8	23
51	The Impact of Clinical and Demographic Variables on Cognitive Performance in Methamphetamine-Dependent Individuals in Rural South Carolina. American Journal on Addictions, 2011, 20, 447-455.	1.4	22
52	Impaired Cognitive Performance in Subjects with Methamphetamine Dependence during Exposure to Neutral versus Methamphetamine-Related Cues. American Journal of Drug and Alcohol Abuse, 2012, 38, 251-259.	2.1	22
53	Approach bias modification for cannabis use disorder: A proof-of-principle study. Journal of Substance Abuse Treatment, 2018, 87, 16-22.	2.8	22
54	Early Life Trauma and Sensitivity to Current Life Stressors in Individuals With and Without Cocaine Dependence. American Journal of Drug and Alcohol Abuse, 2008, 34, 389-396.	2.1	21

#	Article	IF	CITATIONS
55	Influence of cocaine dependence and early life stress on pituitary–adrenal axis responses to CRH and the Trier social stressor. Psychoneuroendocrinology, 2010, 35, 1492-1500.	2.7	19
56	Dâ€cycloserine combined with cue exposure therapy fails to attenuate subjective and physiological craving in cocaine dependence. American Journal on Addictions, 2015, 24, 217-224.	1.4	18
57	Consideration of sex and gender differences in addiction medication response. Biology of Sex Differences, 2022, 13 , .	4.1	18
58	Psychoticism and neuroticism predict cocaine dependence and future cocaine use via different mechanisms. Drug and Alcohol Dependence, 2011, 116, 80-85.	3.2	17
59	Associations between behavioral disinhibition and cocaine use history in individuals with cocaine dependence. Addictive Behaviors, 2012, 37, 1185-1188.	3.0	17
60	Therapeutic Benefit of Smoked Cannabis in Randomized Placeboâ€Controlled Studies. Pharmacotherapy, 2018, 38, 80-85.	2.6	17
61	Impact of cannabis legalization on treatment and research priorities for cannabis use disorder. International Review of Psychiatry, 2018, 30, 216-225.	2.8	17
62	Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population. Journal of Studies on Alcohol and Drugs, 2019, 80, 572-577.	1.0	16
63	Characteristics of cocaine- and marijuana-dependent subjects presenting for medication treatment trials. Addictive Behaviors, 2007, 32, 1433-1440.	3.0	15
64	Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology. Pharmacology Biochemistry and Behavior, 2019, 179, 22-26.	2.9	15
65	ALCOHOL AND SUBSTANCE ABUSE. Medical Clinics of North America, 2001, 85, 779-801.	2.5	14
66	Impact of gender on corticotropinâ€releasing factor and noradrenergic sensitivity in cocaine use disorder. Journal of Neuroscience Research, 2017, 95, 320-327.	2.9	14
67	Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology, 2020, 237, 479-490.	3.1	14
68	Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug and Alcohol Dependence, 2018, 187, 270-277.	3.2	13
69	A case series exploring the effect of twenty sessions of repetitive transcranial magnetic stimulation (rTMS) on cannabis use and craving. Brain Stimulation, 2020, 13, 265-266.	1.6	13
70	Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug and Alcohol Dependence, 2021, 229, 109111.	3.2	13
71	Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. Drug and Alcohol Dependence, 2017, 176, 14-20.	3.2	11
72	Impact of endogenous progesterone on reactivity to yohimbine and cocaine cues in cocaine-dependent women. Pharmacology Biochemistry and Behavior, 2018, 165, 63-69.	2.9	11

#	Article	IF	Citations
73	A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem. Sleep Medicine, 2021, 84, 142-153.	1.6	10
74	Methods to reduce the incidence of false negative trial results in substance use treatment research. Current Opinion in Psychology, 2019, 30, 35-41.	4.9	9
75	Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder Psychology of Addictive Behaviors, 2022, 36, 505-514.	2.1	9
76	Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking. Neurobiology of Stress, 2021, 15, 100364.	4.0	8
77	Reversible Elevation of Triglycerides in Dual-Diagnosis Patients Taking Aripiprazole. Journal of Clinical Psychopharmacology, 2008, 28, 464-467.	1.4	7
78	An Open-Label Trial of Aripiprazole Treatment in Dual Diagnosis Individuals: Safety and Efficacy. Journal of Dual Diagnosis, 2009, 5, 83-96.	1.2	7
79	Safety and Tolerability of Acamprosate in Alcohol-dependent Individuals With Bipolar Disorder. Addictive Disorders and Their Treatment, 2009, 8, 33-38.	0.5	7
80	Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug and Alcohol Dependence, 2021, 218, 108383.	3.2	7
81	Cannabis Withdrawal in Adults With Attention-Deficit/Hyperactivity Disorder. primary care companion for CNS disorders, The, 2018, 20, .	0.6	7
82	A preliminary investigation of the role of intraindividual sleep variability in substance use treatment outcomes. Addictive Behaviors, 2022, 131, 107315.	3.0	6
83	Methylphenidate Transdermal System in Adults With Past Stimulant Misuse. Journal of Attention Disorders, 2011, 15, 539-544.	2.6	5
84	Cannabis Use Disorder as aÂDevelopmental Disorder. , 2019, , 189-199.		5
85	Assessment of Club Drug Use in a Treatment-Seeking Sample of Individuals with Marijuana Dependence. American Journal on Addictions, 2007, 16, 484-487.	1.4	4
86	Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder. Current Addiction Reports, 2020, 7, 545-552.	3.4	3
87	Neurotransmitter and Neuropeptide Targets for Cannabis Use Disorder Treatment. , 2019, , 207-211.		1
88	Sex and drug differences in stress, craving and cortisol response to the trier social stress task. Psychopharmacology, 2022, , .	3.1	1